FeesSafety
Pluang+

Johnson & Johnson stock seen as a strong defensive buy with 15.6% upside potential despite recent slip.

Analyst Insights
19 Oct 2026, 14:15 WIB
24/7 Wall Street
View Source
Bullish
Johnson & Johnson stock seen as a strong defensive buy with 15.6% upside potential despite recent slip.

Johnson & Johnson reported a solid quarter with 6% sales growth and strong oncology business expansion, despite a slight miss in MedTech. Analysts maintain a bullish outlook with a 12-month price target of $291.60, implying a 15.6% upside from current levels. The company’s long history of dividend increases and diversified portfolio support its defensive stock status. Key growth drivers include the TREMFYA franchise and oncology segment, while risks involve recent deal dilution and MedTech performance. The stock trades at a premium compared to peers but offers stability and growth potential for investors.

Johnson & Johnson's reputation as a defensive stock aligns with its current trading status on Pluang, where it is priced at USD 253.79 as of Oct 19, 2026, 18:12 WIB. The stock has seen a slight dip of 0.69% in one day but maintains a dividend yield of 2.1%, reflecting its appeal for income-focused investors. With a market cap of $615.87 billion and a 52-week high of $278.43, JNJ remains a significant player in the health sector on Pluang.

More News (JNJ)

Johnson & Johnson remains a strong dividend stock but trades at a premium valuation.

Johnson & Johnson remains a strong dividend stock but trades at a premium valuation.

Johnson & Johnson continues to show resilience with a 64-year dividend increase streak and raised full-year revenue and earnings guidance for 2026. Despite its strong business fundamentals and leadership in pharmaceuticals and medical devices, the st...

Company Fundamentals
Bullish
6 hours ago
Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson and Pfizer are key healthcare giants with differing strategies: J&J balances drug innovation and medical devices, while Pfizer focuses on oncology and obesity treatments. J&J reported stronger revenue growth and higher net income, w...

Market News
Neutral
7 hours ago
Johnson & Johnson remains a strong dividend stock but is pricey for value investors now.

Johnson & Johnson remains a strong dividend stock but is pricey for value investors now.

Johnson & Johnson continues to lead in pharmaceuticals and medical devices, boasting a 64-year streak of dividend increases. The company recently raised its full-year revenue and earnings guidance, reflecting solid business performance. However, its ...

Company Fundamentals
Bullish
11 hours ago
Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson and Pfizer, two healthcare giants, are taking different growth paths heading into 2027. Johnson & Johnson maintains a balanced business with strong pharmaceutical and medical device segments, showing steady revenue growth and a soli...

Market News
Neutral
12 hours ago
Dow drops nearly 950 points into correction as tech sell-off spreads and Fed rate hike looms

Dow drops nearly 950 points into correction as tech sell-off spreads and Fed rate hike looms

The Dow Jones Industrial Average fell nearly 950 points on Friday, entering correction territory by closing over 10% below its record high. The sell-off was driven by continued weakness in technology stocks, including a 14% drop in Nvidia after SEC a...

Bearish
15 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App